NASDAQ: BYAHPark Ha Biological Technology Co Ltd Stock
$1.47+0.42 (+40%)
Updated Jun 12, 2026
BYAH Price
$1.47
Fair Value Price
N/A
Market Cap
$995.91k
52 Week Low
$0.94
52 Week High
$2,068.60
P/E
-0.04x
P/B
0.25x
P/S
4.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.52M
Earnings
-$24.36M
Gross Margin
94.4%
Operating Margin
-953.88%
Profit Margin
-965%
Debt to Equity
0.49
Operating Cash Flow
$86k
Beta
0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BYAH Overview
This enterprise functions as an investment holding company, with its core business centered on crafting and distributing skincare solutions. Operating under the "Park Ha" brand, these products are sold across the People's Republic of China. The company executes these activities through its affiliated subsidiaries, which manage both direct product sales and the provision of franchise services.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BYAH's potential to beat the market
- BYAH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Household & Personal Product
Industry Rating
D
BYAH
RankedUnranked of 20
RankedUnranked of 20
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $83.30 | B | |
| $29.86 | C | |
| $89.68 | C |
Be the first to know about important BYAH news, forecast changes, insider trades & much more!
BYAH News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BYAH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BYAH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BYAH is good value based on its book value relative to its share price (0.25x), compared to the US Household & Personal Products industry average (6.6x)
P/B vs Industry Valuation
BYAH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BYAH due diligence checks available for Premium users.
Valuation
BYAH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
9.32x
Market
14.15x
BYAH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.25x
Industry
6.6x
BYAH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BYAH's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BYAH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BYAH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.0M
Liabilities
$2.0M
Debt to equity
0.49
BYAH's short-term assets ($5.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYAH's short-term assets ($5.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYAH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYAH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BYAH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BYAH vs Household & Personal Product Stocks
Park Ha Biological Technology Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.